Compare Twist Bioscience Corp (TWST) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Workiva Inc — how do they compare? Twist Bioscience Corp trades at $156.21 (market cap $10.08B), while Workiva Inc trades at $75.4 (market cap $4.01B). The key difference: Twist Bioscience Corp is far larger — about 2.5× Workiva Inc's market cap, and Twist Bioscience Corp is more actively traded (4,229,037 versus 1,301,708). Which is the better fit depends on your goals — on Pluang, investors hold Twist Bioscience Corp for 27 Days and Workiva Inc for 21 Days on average.
| TWST | WK | |
|---|---|---|
Market Cap | $10.08B | $4.01B |
Volume | 4,229,037 | 1,301,708 |
Sector | Health | Technology |
52-Week High | $205.00 | $93.31 |
52-Week Low | $25.45 | $44.31 |
Typical Hold Time | 27 Days | 21 Days |
Enterprise Value | $10.01B | $3.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TWST trades at $155.65, down 6.78% today, reflecting a bearish technical signal and recent earnings misses. Revenue growth is strong, rising to $376.57M in 2025, but profitability remains elusive with a net income margin of -31.66%. The company's partnership with Lilly TuneLab for AI-driven drug discovery has generated positive news flow, yet cash flow remains negative, and the stock trades at elevated valuation multiples like P/S of 22.01.
The outlook is mixed: strong analyst buy-side consensus (73% Buy) and strategic AI partnerships offer growth potential, but persistent losses, high cash burn, and bearish technicals pose significant risks. Investors face a trade-off between long-term innovation prospects and near-term financial instability.
WK trades at $71.53, up 1.95% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and analyst consensus of $86 price target. Revenue grew to $966M in 2026 with net income turning positive at $47M. Recent news highlights AI innovation and inclusion in major indices, supporting positive sentiment.
The outlook remains positive with 89% analyst buy ratings and improving profitability. Key risks include high valuation multiples (P/E 87.7) and competitive pressures in the regulatory software space. The stock offers growth potential but requires monitoring of execution against elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
